Keyphrases
Nanoparticles
57%
Granules
56%
Docetaxel
43%
Self-assembled Nanoparticles
27%
Lipid-based
26%
Oral Docetaxel
26%
In Situ Self-assembly
25%
Ritonavir
18%
Multidrug Resistance
18%
Lipid Nanoparticles
18%
Oral Absorption
17%
Biodistribution
17%
Maximum Tolerated Dose
17%
Docetaxel-resistant
17%
Doxorubicin
17%
Blood-brain Barrier
17%
Nerve Growth Factor
17%
High-density Lipoprotein Cholesterol (HDL-C)
17%
Lopinavir
17%
Toxicity Evaluation
17%
Dose Evaluation
17%
Sorafenib
17%
Orally Administered
17%
P-glycoprotein (P-gp)
14%
Paclitaxel
14%
Castration-resistant Prostate Cancer
12%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
12%
Poorly Water-soluble Drugs
11%
Anticancer Activity
11%
Paclitaxel Nanoparticles
11%
Multidrug Resistance Reversal
10%
Drug Loading
10%
Solid Lipid Nanoparticles
9%
Cytotoxicity
9%
Brain Drug Delivery
9%
Commercially Available
9%
Castration-resistant Prostate Cancer Cells
9%
Nanoformulation
8%
Drug-resistant Tumor
8%
Alcohol Dehydrogenase
8%
Growth Evaluation
8%
Dissolution Method
8%
Oral Suspension
8%
Quetiapine Fumarate
8%
Oral Formulation
8%
Biorelevant Dissolution
8%
Sequential Simplex Optimization
8%
Child-friendly
8%
Idarubicin
8%
Oral Solids
8%
Pharmacology, Toxicology and Pharmaceutical Science
Nanoparticle
100%
Docetaxel
51%
Multidrug Resistance
25%
Ritonavir
18%
Biodistribution
17%
Castration Resistant Prostate Cancer
17%
High Density Lipoprotein
17%
Nerve Growth Factor
17%
Paclitaxel
17%
Doxorubicin
17%
Sorafenib
17%
Maximum Tolerated Dose
17%
Blood-Brain Barrier
17%
P-Glycoprotein
13%
Surfactant
12%
Cytotoxicity
12%
Chemotherapy
12%
Neoplasm
12%
Lopinavir
11%
Microemulsions
11%
Lopinavir Plus Ritonavir
10%
Bioavailability
10%
Solid Lipid Nanoparticle
9%
Solid Lipid Nanoparticle
9%
Drug Delivery System
9%
Malignant Neoplasm
9%
Tablet
9%
High Performance Liquid Chromatography
9%
Tocopherol
8%
Lung Cancer
8%
Subcutaneous Injection
8%
Idarubicin
8%
Metformin
8%
Leukemia
8%
Quetiapine
8%
Curcumin
8%
Adenosine Triphosphate
8%
Alcohol Dehydrogenase
8%
Fatty Alcohol
8%
Lipid-Based Drug Delivery System
7%
Polyoxyethylene Stearyl Ether
5%